HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Hematology patterns after hemoglobin-based oxygen carrier resuscitation from severe controlled hemorrhage with prolonged delayed definitive care.

AbstractBACKGROUND:
The hemoglobin-based oxygen carrier (HBOC-201) resuscitation fluid improves outcome in hemorrhagic shock swine models with minimal coagulopathy. Herein, coagulation parameters were evaluated after resuscitation with HBOC-201 after severe bleeding and prolonged delay to definitive care.
STUDY DESIGN AND METHODS:
After 55 percent estimated blood volume-controlled hemorrhage by catheter withdrawal, swine (n=48) were resuscitated with HBOC-201 or Hextend (HEX) infused in four doses over 4 hours or not resuscitated (NON). Animals were randomly assigned in two cohorts of 4- or 24-hour simulated delay to hospital arrival (access to blood and saline infusions up to 72 hr). In vitro hematologic monitoring was assessed with complete blood count, hemostasis (thromboelastography [TEG], in vitro bleeding time [PFA]), and coagulation (prothrombin time [PT], thrombin-antithrombin, fibrinogen) indices.
RESULTS:
Within groups, survival was unaffected by extending delay from 4 to 24 hours. Combined survival was similar for HBOC-201 and HEX but lower for NON animals (93.5, 81.5, and 25 percent, respectively; p<0.01). Blood transfusion requirements were lower with HBOC-201 than HEX. Elevated TEG and PFA parameters in resuscitated animals reflected fluid and blood transfusion regimens. TEG reaction time and PFA were transiently higher with HBOC-201 than with HEX during the early hospital phase. PT was increased in HEX animals.
CONCLUSION:
In this severe model, survival was equivalent with HBOC-201 and HEX resuscitation. HBOC-201 or HEX allowed delayed hospital arrival to 24 hours without worsening coagulation parameters, but dilutional mild coagulopathy in the hospital phase persisted with HBOC-201 due to blood transfusion avoidance. Low hematocrit suggests that blood administration after HBOC-201 resuscitation could be beneficial to replete blood cellular mass.
AuthorsFrancoise Arnaud, Daniel Fasipe, Nora Philbin, Jennifer Rice, W Shannon Flournoy, Stephen Ahlers, Richard McCarron, Daniel Freilich
JournalTransfusion (Transfusion) Vol. 47 Issue 11 Pg. 2098-109 (Nov 2007) ISSN: 0041-1132 [Print] United States
PMID17958540 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Blood Substitutes
  • Hemoglobins
  • HBOC 201
Topics
  • Animals
  • Blood Coagulation
  • Blood Coagulation Tests
  • Blood Substitutes (therapeutic use)
  • Blood Transfusion
  • Hematologic Tests
  • Hemoglobins (therapeutic use)
  • Hemorrhage (therapy)
  • Resuscitation (methods)
  • Swine
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: